Ligand Pharmaceuticals, Inc. (LGND) – Financial and Strategic SWOT Analysis Review

Ligand Pharmaceuticals, Inc. (LGND) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
60
Pharmaceuticals and Healthcare
United States

Ligand Pharmaceuticals, Inc. (LGND) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ligand Pharmaceuticals, Inc. (Ligand), formerly Progenx Inc., is a biopharmaceutical company. It focuses on developing programmes for unmet medical needs, and acquiring revenue generating assets to generate substantial cash flow and profits. The company has a diversified portfolio of assets across numerous technology types, drug targets, therapeutic areas and industry partners. It has various royalty-generating assets in the industry to address unmet medical needs in the therapeutic areas of thrombocytopenia, diabetes, hepatitis, multiple myeloma, asthma, Alzheimer’s disease, fungal infections, muscle wasting, dyslipidemia, anemia and osteoporosis.

Ligand Pharmaceuticals, Inc. Key Recent Developments

Feb 09, 2015 Ligand Reports Fourth Quarter and Full Year 2014 Financial Results
Feb 02, 2015 Ligand Promotes Matthew W. Foehr to President
Nov 18, 2014 Ligand Provides Highlights from Analyst Day Event
Oct 27, 2014 Ligand Reports Third Quarter 2014 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Ligand Pharmaceuticals, Inc. – Key Facts 6
Ligand Pharmaceuticals, Inc. – Key Employees 7
Ligand Pharmaceuticals, Inc. – Key Employee Biographies 8
Ligand Pharmaceuticals, Inc. – Major Products and Services 9
Ligand Pharmaceuticals, Inc. – Pharmaceutical Pipeline Products Data 10
Ligand Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Ligand Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Ligand Pharmaceuticals, Inc. – History 14
Ligand Pharmaceuticals, Inc. – Company Statement 20
Ligand Pharmaceuticals, Inc. – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Section 2 – Company Analysis 23
Ligand Pharmaceuticals, Inc. – Business Description 23
Ligand Pharmaceuticals, Inc. – Corporate Strategy 24
Ligand Pharmaceuticals, Inc. – SWOT Analysis 25
SWOT Analysis – Overview 25
Ligand Pharmaceuticals, Inc. – Strengths 25
Strength – Alliances and Partnerships 25
Strength – Increase in Revenue 25
Strength – Research & Development Capabilities 25
Ligand Pharmaceuticals, Inc. – Weaknesses 26
Weakness – Dependence on Royalties of Kyprolis and Promacta 26
Weakness – Increasing Trade Receivables 26
Ligand Pharmaceuticals, Inc. – Opportunities 27
Opportunity – Regulatory Approvals 27
Opportunity – Changing Demographics 27
Opportunity – Robust Product Pipeline 27
Ligand Pharmaceuticals, Inc. – Threats 28
Threat – Lack of Manufacturing Facilities 28
Threat – Tightening of the FDA’s Regulatory Oversight 28
Threat – Uncertain R&D Outcomes 28
Ligand Pharmaceuticals, Inc. – Key Competitors 29
Section 3 – Company Financial Ratios 30
Financial Ratios – Capital Market Ratios 30
Financial Ratios – Annual Ratios 31
Performance Chart 33
Financial Performance 33
Financial Ratios – Interim Ratios 34
Financial Ratios – Ratio Charts 35
Section 4 – Company’s Lifesciences Financial Deals and Alliances 36
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 36
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 37
Ligand Pharmaceuticals, Inc., Recent Deals Summary 38
Section 5 – Company’s Recent Developments 39
Feb 09, 2015: Ligand Reports Fourth Quarter and Full Year 2014 Financial Results 39
Feb 02, 2015: Ligand Promotes Matthew W. Foehr to President 42
Nov 18, 2014: Ligand Provides Highlights from Analyst Day Event 43
Oct 27, 2014: Ligand Reports Third Quarter 2014 Financial Results 44
Oct 08, 2014: Ligand Reports Third Quarter Revenues and Expected Diluted EPS 47
Aug 04, 2014: Ligand Reports Second Quarter 2014 Financial Results 48
Jul 23, 2014: Ligand Partner GSK Announces Record Quarterly Promacta/Revolade Revenue of $92 Million 51
Jul 17, 2014: Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program 52
Jul 14, 2014: Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum 53
Mar 11, 2014: Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference 55
Section 6 – Appendix 56
Methodology 56
Ratio Definitions 56
About GlobalData 60
Contact Us 60
Disclaimer 60



List of Tables
Ligand Pharmaceuticals, Inc., Key Facts 6
Ligand Pharmaceuticals, Inc., Key Employees 7
Ligand Pharmaceuticals, Inc., Key Employee Biographies 8
Ligand Pharmaceuticals, Inc., Major Products and Services 9
Ligand Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Ligand Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Ligand Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12
Ligand Pharmaceuticals, Inc., History 14
Ligand Pharmaceuticals, Inc., Subsidiaries 21
Ligand Pharmaceuticals, Inc., Key Competitors 29
Ligand Pharmaceuticals, Inc., Ratios based on current share price 30
Ligand Pharmaceuticals, Inc., Annual Ratios 31
Ligand Pharmaceuticals, Inc., Interim Ratios 34
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 36
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 37
Ligand Pharmaceuticals, Inc., Recent Deals Summary 38
Currency Codes 56
Capital Market Ratios 56
Equity Ratios 57
Profitability Ratios 57
Cost Ratios 58
Liquidity Ratios 58
Leverage Ratios 59
Efficiency Ratios 59



List of Figures
Ligand Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Ligand Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Ligand Pharmaceuticals, Inc., Performance Chart (2010 – 2014) 33
Ligand Pharmaceuticals, Inc., Ratio Charts 35
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 36
Ligand Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 37

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.